Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/28/2007US20070149587 Valsartan Salts
06/28/2007US20070149586 New crystalline and stable form of andolast
06/28/2007US20070149585 Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists
06/28/2007US20070149584 Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
06/28/2007US20070149583 Diazonamide a analog
06/28/2007US20070149582 1-(Azolin-2-yl)amino-1,2-diphenylethane compounds for combating insects, arachnids and nematodes
06/28/2007US20070149581 Potent immunosuppressive agents derivatives and use
06/28/2007US20070149580 Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
06/28/2007US20070149579 e.g. 4-bromo-N-{[4-(4-fluorophenyl)-2-oxo-2H-chromen-7-yl]methyl}-N-{5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl}benzamide;leukotriene biosynthesis and 5-lipoxygenase (5-LO); inhibitor; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents
06/28/2007US20070149578 Combination Therapy
06/28/2007US20070149577 Compounds with medicinal effects due to interaction with the glucocorticoid receptor
06/28/2007US20070149575 5-Aminoalkylpyrazole derivatives as pesticidal agents
06/28/2007US20070149574 N-(3,5-Dimethylphenyl)-2-[2-(4-methylpiperazin-1-yl)pyridin-4-ylmethylthio]pyridine-3-carboxamide; 2-(2-Cyclopropylaminopyridin-4-ylmethylthio)-N-(3,5-dimethylphenyl)pyridine-3-carboxamide; cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity
06/28/2007US20070149573 99.9% By weight of amorphous S-omeprazole magnesium, <0.1% by weight of impurities as determined by liquid chromatography; X-ray powder diffractogram; substantially free of neutral omeprazole; optical purity 94-96% e.e.; anhydrous; industrial scale; materials handling; filterable
06/28/2007US20070149572 Method of inhibiting flt3 kinase
06/28/2007US20070149571 Combination therapy for treating or managing acute myelocytic leukemia
06/28/2007US20070149570 Piperidine derivative and use thereof
06/28/2007US20070149569 Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
06/28/2007US20070149568 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
06/28/2007US20070149567 Quinoline compounds
06/28/2007US20070149566 e.g. 4-({(E)-4-[(2-carboxy-6-fluoro-4-quinolinyl)oxy]-2-butenyl}oxy)-6-fluoroquinoline-2-carboxylic acid; antidiabetic, hypoglycemic agent; type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia
06/28/2007US20070149565 Nelfinavir conjugates and antibodies useful in immunoassay
06/28/2007US20070149564 Estrogen modulators
06/28/2007US20070149563 N-(1-Azabicyclo[2.2.2]oct-3-yl)(2-(3-pyridyl)thiazole-4-carboxamide); nicotinic acetylcholine receptor ligands; psychotic and intellectual impairment disorders; antidepressant, anxiolytic agent; Alzheimer's disease, cognitive or attention disorders
06/28/2007US20070149562 Oxopiperidine derivatives, preparation and therapeutic use thereof
06/28/2007US20070149561 Azaindole inhibitors of aurora kinases
06/28/2007US20070149560 Novel fused triazolones and the uses thereof
06/28/2007US20070149559 Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions
06/28/2007US20070149558 Benzo-fused 5-membered heterocyclic compounds, their production and use
06/28/2007US20070149557 CXCR3 antagonists
06/28/2007US20070149556 Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase
06/28/2007US20070149555 Prophylatic and/or therapeutic agents for chronic musculoskeletal pain
06/28/2007US20070149554 Cancer chemotherapy
06/28/2007US20070149553 2,3-Diphenylquinazolin-4(3H)-one compounds; anticarcinogenic agents can be synergistically combined with one or more active ingredients; side effect reduction
06/28/2007US20070149552 Lyophilized compositions of a triazolopyrimidine compound
06/28/2007US20070149551 crop protection agents for controlling harmful fungi; improved activity; [6-chloro-2-(N'-isopropylidene-hydrazino)-5-(2,4,6-trifluorophenyl)pyrimidine-4-yl]-((S)-1-tri-fluoromethylethyl)amine; against Septoria Leaf Blotch of Wheat, Net Blotch of Barley and Mildew of Cucumber
06/28/2007US20070149550 Substituted arylpyrazoles
06/28/2007US20070149549 Prenylation Inhibitors and Methods of Their Synthesis and Use
06/28/2007US20070149548 For rho kinase-mediated diseases; (S)-N1-[6-(3-Methyl-1H-indazole-5-yl)-pyrazin-2-yl]-3-phenyl-propane-1,2-diamine dihydrochloride; eye disorders
06/28/2007US20070149547 Bipyridyl amides as modulators of metabotropic glutamate receptor-5
06/28/2007US20070149546 4-Anilino-quinazoline derivatives as antiproliferative agents
06/28/2007US20070149545 Substituted indan derivatives
06/28/2007US20070149544 Biaryl nitrogen-heterocycle inhibitors of lta4h for treating inflammation
06/28/2007US20070149543 Agents For Treating Neurodegenerative Diseases
06/28/2007US20070149542 Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
06/28/2007US20070149541 Imidazole compounds
06/28/2007US20070149540 Crystal of 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate; antibacterial activity; preferentially precipitated by controlling supersaturation concentration in crystalization using acetonitrile
06/28/2007US20070149539 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
06/28/2007US20070149538 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
06/28/2007US20070149537 NK1 and NK2-antagonists and compositions and methods of using the same
06/28/2007US20070149536 2-[4-Bromomethyl)phenyl-3-phenylquinoxaline 1-2; selectively inhibits one or two of the serine/threonine protein kinase isoforms; antiproliferative
06/28/2007US20070149535 Protein kinase inhibitors
06/28/2007US20070149534 Inhibit tyrosine kinase activity of Trk receptors; antiproliferative agents, anticancer agents; cancer, psoriasis or rheumatoid arthritis; 1-(5-{[4-amino-7-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]carbonyl}-3-pyridinyl)-3-(2,4-dichlorophenyl)urea
06/28/2007US20070149533 Bicyclic compounds with kinase inhibitory activity
06/28/2007US20070149532 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors
06/28/2007US20070149531 Antiviral agents
06/28/2007US20070149530 Antiviral agents
06/28/2007US20070149529 inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, autoimmune pathologies such as rheumatoid arthritis and atherosclerosis
06/28/2007US20070149528 rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis; reduced drug toxicity
06/28/2007US20070149527 New treatments for nervous disorders
06/28/2007US20070149526 Diuretic and diuretic-like compound analogs
06/28/2007US20070149525 Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
06/28/2007US20070149524 Substituted diketopiperazines and their use as oxytocin antagonists
06/28/2007US20070149523 Thiazole Analogues and Uses Thereof
06/28/2007US20070149522 Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
06/28/2007US20070149521 Prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system; 1-(3-Benzyloxy-phenyl)-3-ethoxy-imidazo[1,5-a]pyrazin-8-ylamine
06/28/2007US20070149520 HCV Inhibitors And Methods Of Using Them
06/28/2007US20070149519 Benzimidazol substituted thiopene derivatives with activity on ikk3
06/28/2007US20070149518 Oxazoloisoquinoline derivatives as thrombin receptor antagonists
06/28/2007US20070149517 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity
06/28/2007US20070149516 to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide
06/28/2007US20070149514 Indole-phenylsulfonamide derivatives used as ppar-delta activating compounds
06/28/2007US20070149513 Vanilloid receptor ligands and their use in treatments
06/28/2007US20070149512 N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
06/28/2007US20070149511 Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof
06/28/2007US20070149510 Quinazolinone and benzoxazinone derivatives and uses thereof
06/28/2007US20070149509 Use of vitamin e
06/28/2007US20070149508 Six membered heteroaromatic inhibitors targeting resistant kinase mutations
06/28/2007US20070149507 Process for preparing oxcarbazepine
06/28/2007US20070149506 Azepine inhibitors of Janus kinases
06/28/2007US20070149505 Method of Inhibiting Adhesion Formation
06/28/2007US20070149504 Use of neurokinin antagonists in the treatment of urinary incontinence
06/28/2007US20070149503 Anti-migraine spirocycles
06/28/2007US20070149502 Spirocyclic anti-migraine compounds
06/28/2007US20070149501 Process for the preparation of diphenyl azetidinone derivatives
06/28/2007US20070149500 Compounds, compositions, and methods
06/28/2007US20070149499 Process for preparing beta-lactamase inhibitors
06/28/2007US20070149498 Cancer therapy
06/28/2007US20070149497 A tetrapyrollic photosensitizer compound having at least one pendant CH2CH2CON(CH2CON(CH2COOH)2)2 or N(CH2COOH)2 group, being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide
06/28/2007US20070149496 Water-soluble compound
06/28/2007US20070149495 Histone deacetylase inhibitors
06/28/2007US20070149494 Method for producing 5alpha-pregnane derivative
06/28/2007US20070149493 Sustained release hydrocortisone treatment
06/28/2007US20070149492 Method of affecting sleep and sleep-related behaviors
06/28/2007US20070149491 Compounds useful for treating neurodegenerative disorders
06/28/2007US20070149490 process for the extraction of betulinic acid
06/28/2007US20070149489 Preparation of paricalcitol
06/28/2007US20070149488 Tetracycline Derivatives and Methods of Use Thereof
06/28/2007US20070149487 Antiviral Compositions and Methods
06/28/2007US20070149486 Process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts
1 ... 3691 3692 3693 3694 3695 3696 3697 3698 3699 3700 3701 3702 3703 3704 3705 3706 3707 3708 3709 3710 3711 ... 7860